Compare · ABT vs AVDL
ABT vs AVDL
Side-by-side comparison of Abbott Laboratories (ABT) and Avadel Pharmaceuticals plc (AVDL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and AVDL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $197.44B, about 432.5x AVDL ($456.5M).
- Over the past year, ABT is down 13.2% and AVDL is up 45.8% - AVDL leads by 59.0 points.
- ABT has hit the wire 8 times in the past 4 weeks while AVDL has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 15 for AVDL).
- Company
- Abbott Laboratories
- Avadel Pharmaceuticals plc
- Price
- $114.08-1.75%
- $21.67+0.16%
- Market cap
- $197.44B
- $456.5M
- 1M return
- +6.30%
- +0.77%
- 1Y return
- -13.18%
- +45.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 15
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest AVDL
- SEC Form 15-12G filed by Avadel Pharmaceuticals plc
- Former 10% Owner Weiss Asset Management Lp sold $233,353,092 worth of Ordinary Shares (11,112,052 units at $21.00) (SEC Form 4)
- New insider Weiss Asset Management Lp claimed ownership of 11,112,052 units of Ordinary Shares (SEC Form 3)
- Amendment: SEC Form SCHEDULE 13G/A filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form 4 filed by Chief Operating Officer Rodriguez Susan
- Director Thornton Peter J. returned $2,416,260 worth of Ordinary Shares to the company (115,060 units at $21.00), closing all direct ownership in the company (SEC Form 4)